Think of 8

CCC_logoOur Non-Profit Partner
Jeevan Biosciences, Inc. (JBI) has teamed up with Community & Children In Crisis, Inc. (CCC) on this very important initiative. CCC is a charitable organization dedicated to working with children, families, and their communities. Working with CCC allow them to provide JBI with funding for breakthrough cancer research.
Through the generosity of private donors, the cost of CCC general operations are covered. That means 100% of your money will go straight to cancer research!
Jeevan Biosciences Inc. is establishing the very first cancer stem cell library for medical research. We want to see women of different ancestries beat breast cancer by creating treatment that is specific for the patient and not just for treating breast cancer.

At Jeevan Biosciences Inc., we are on the forefront of bringing ancestry and drug development together. We embrace genetic diversity through our research.

Our Story
Did you know that one out of eight women are at risk of death caused by breast cancer?

Overarching Challenge:
Breast cancer is one of the most common cancers among American women. Breast cancer is also a global problem, accounting for nearly a quarter of all cancers in women. It is estimated that globally, 1.7 million women are diagnosed with breast cancer annually. About 1 in 8 (12%) women in the US will develop invasive breast cancer during their lifetime. The chance that breast cancer will be responsible for a woman’s death is about 1 in 36 (about 3%). Genetic diversity is the determining factor behind why some women are more likely to receive a diagnosis of breast cancer, while others are more likely to die from breast cancer. In addition, studies have demonstrated that some women tend to have a more advanced stage of disease at the time of diagnosis.

Genetic diversity is a contributing factor in why some women develop a more aggressive and deadly form of the disease, commonly referred to as Triple-negative breast cancer (TNBC). TNBCs have a relapse pattern that is very different from other breast cancers, and many hypothesize that there are subgroups of patients with treatment-resistant TNBC, which is initiated and maintained by cancer stem cells. Although breast cancers are very different and their growth can vary from person to person, the majority of women with breast cancer still receive the same treatment, as though the breast cancers were all the same. Despite decades of advancement in breast cancer research, there are no FDA approved therapies for triple negative breast cancer. The battle against this disease is still ongoing.

Please download the full Think of 8 Overview